Interestingly, tumor-infiltrating lymphocytes were increased by treatment in both study arms [80], suggesting that while blocking PD-1 may activate a clinically relevant TNBC-targeting immune response in this patient population, ICD induction by chemotherapy may be required to enable abundant tumor infiltration by immune effector cells. Here, PDCD1 is linked to neoplasm.